Edwards Lifesciences recently announced that it would acquire Innovalve Bio Medical, an early-stage transcatheter mitral valve replacement (“TMVR”) company. Edwards had the option to acquire Innovalve ...

Early feasibility study results are promising for AltaValve, which is designed with a novel atrial fixation system to ...

The transcatheter mitral valve replacement (TMVR) market is projected to grow at a CAGR of 20% over the forecast period. Major factors driving growth include increased prevalence of mitral valve ...

Leaflet modification technique developed to prevent LVOT obstruction ...

For patients with significant mitral regurgitation (MR) who are unsuitable for surgical intervention or transcatheter edge-to-edge repair (TEER), transcatheter mitral valve replacement (TMVR) appears ...

After years of interest in and anticipation about the potential for transcatheter mitral valve replacement (TMVR), Edwards Lifesciences is ready to kick off a CE Mark trial for its TMVR system. The ...

Edwards Lifesciences, MD+DI's 2016 Medtech Company of the Year, pioneered transcatheter aortic valve replacement and has remained the top player in the market. Can the valve powerhouse repeat its ...

Intentionally tearing the anterior mitral valve leaflet may prevent one of the most serious and life-threatening complications of transcatheter mitral valve replacement (TMVR)—left ventricular outflow ...

Edwards Lifesciences (EW) announced on Tuesday that the U.S. Food and Drug Administration approved its SAPIEN M3 transcatheter mitral valve replacement (TMVR) system for patients with mitral ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve ...